Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells

Japanese Journal of Pharmacology

Volumn 70, Issue 1, 1996, Pages 65-72

  Ikegami, Yuri ^a   Yano, Seiichi ^a   Nakao, Kenzo ^a  

^a CIBA GEIGY LTD   (Switzerland)

Author keywords

Cell cycle; CGP41251; G2 M arrest; Human non small cell lung cancer; Protein kinase C inhibitor

Indexed keywords

MIDOSTAURIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPLICATION; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; METAPHASE; MITOSIS INHIBITION; MOUSE; NUDE MOUSE; ORAL DRUG ADMINISTRATION; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

EID: 0030022970     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.70.65     Document Type: Article

References (26)

1. Nishizuka Y: Studies and perspectives of protein kinase C. Science 233, 305-312 (1986)
2. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implication for cellular regulation. Nature 334, 661-665 (1988)
3. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 253, 607-614 (1992)
4. Stabel S and Parker P: Protein kinase C. Pharmacol Ther 51, 71-95 (1991)
5. Osada SI, Mizuno K, Saido TC, Suzuki K, Kuroki T and Ohno S: A new member of the protein kinase C family, nPKC-q, predominantly expressed in skeletal muscle. Mol Cell Biol 12, 3930-3938 (1992)
6. Asoaka Y, Nakamura S, Yoshida K and Nishizuka Y: Protein kinase C, calcium and phospholipid degradation. Trends Biochem Sci 17, 414-417 (1992)
7. Housey GM, Johnson MD, Hsiao HLW, O'Brian CA, Murphy JP, Krischmeier P and Weinstein IB: Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell 52, 343-354 (1988)
8. Persons DA, Wilkinson WO, Bell RM and Finn OJ: Altered growth control and enhanced tumorigenicity of NIH 3T3 fibrolbrasts transformed with protein kinase C-l cDNA. Cell 52, 447-458 (1988)
9. Hung M, Chida K, Kamata N, Nose K, Kato M, Homma Y, Takenawa T and Kuroki T: Enhancement of inositol phospholipid metabolism and activation of protein kinase C in rastransformed rat fibroblasts. J Biol Chem 263, 17975-17980 (1988)
10. Delage S, Chastre E, Empereur S, Wicek D, Veissiere D, Capeau J, Gespach C and Cherqui G: Increased protein kinase C α expression in human colonic Caco-2 cell after insertion of human Ha-ras or polyoma virus middle T oncogenes. Cancer Res 53, 2762-2770 (1993)
11. William T, Couldwell MD, Joon H, Uhm BS, Jack P, Antel MD and Voon WY: Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 29, 880-887 (1991)
12. Meyer T, Regenass U, Fabbro D, Alteri E, Rosel J, Muller M, Caravatti G and Matler A: A derivative of staurosporine (CGP41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer 43, 851-856 (1989)
13. Marte BM, Meyer T, Stabel S, Standke GJR, Jaken S, Fabbro D and Hynes NE: Protein kinase C and mammary cell differentiation: Involvement of protein kinase C α in the induction of β-casein expression. Cell Growth Differ 5, 239-247 (1994)
14. Ikegami Y, Yano S, Nakao K, Fujita F, Fujita M, Sakamoto Y, Murata N and Isowa K: Antitumor activity of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on murine and human tumor models. Arzneimittelforschung 45, 1225-1230 (1995)
15. Shimosato Y, Oboshi S and Baba K: Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. J Clin Oncol 1, 19-35 (1971)
16. Hatada T, Sakanoue Y, Kusunoki M, Kobayashi A and Utsunomiya J: Protein kinase C activity in human thyroid carcinoma and adenoma. Cancer 70, 2918-2922 (1992)
17. 2 block caused by staurosporine, a potent inhibitor of protein kinase C. Exp Cell Res 192, 122-127 (1991)
18. Bruno S, Ardelt B, Skierski JS, Traganos F and Darzynkiewicz Z: Different effects of staurosporine, an inhibitor of protein kinase, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res 51, 470-473 (1992)
19. 1 phase of the cell cycle. Proc Natl Acad Sci USA 88, 7580-7584 (1991)
20. Levin DE, Fields OF, Kunisawa R, Bishop JM and Thorner JA: A candidate protein kinase C gene, PKC1, is required for the cerevisiae cell cycle. Cell 62, 213-224 (1990)
21. Usui T, Yoshida M, Abe K, Osada H, Isowa K and Beppu T: Uncoupled cell cycle without mitosis induced by a protein kinase inhibitor, K-252a. J Cell Biol 115, 1275-1282 (1991)
22. Akinaga S, Nomura K, Gomi K and Okabe M: Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother Pharmacol 33, 273-280 (1994)
23. Seynaeve CM, Stetler-Steveson M, Sebers S, Kaur G, Sausville EA and Worland PJ: Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53, 2081-2086 (1993)
24. Yamamoto S, Itsumi K, Aizu E, Nakadate T, Hosoda Y and Kato R: Differential inhibition by staurosporine, a potent protein kinase C inhibitor, of 12-O-tetradecanoylphorbol-13-acetate-caused skin tumor promotion, epidermal ornithine decarboxylase induction, hyperplasia and inflammation. Carcinogenesisl 10, 1315-1322 (1989)
25. Kraft AS, Anderson WB, Cooper HL and Sando JJ: Decrease in cytosolic calcium/phospholipid-dependent protein kinase activity following phorbol ester treatment of EL4 thymoma cells. J Biol Chem 257, 13193-13196 (1982)
26. 2+ phospholipid-dependent protein kinase associated with plasma membrane. Nature 301, 621-623 (1983)